Literature DB >> 16173750

Monitoring the effects of antagonists on protein-protein interactions with NMR spectroscopy.

Loyola D'Silva1, Przemyslaw Ozdowy, Marcin Krajewski, Ulli Rothweiler, Mahavir Singh, Tad A Holak.   

Abstract

We describe an NMR method that directly monitors the influence of ligands on protein-protein interactions. For a two-protein interaction complex, the size of one component should be small enough (less than ca. 15 kDa) to provide a good quality (15)N((13)C) HSQC spectrum after (15)N((13)C) labeling. The size of the second unlabeled component should be large enough so that the molecular weight of the preformed complex is larger than ca. 40 kDa. When the smaller protein binds to a larger one, broadening of NMR resonances results in the disappearance of most of its cross-peaks in the HSQC spectrum. Addition of an antagonist that can dissociate the complex would restore the HSQC spectrum of the smaller component. The method directly shows whether an antagonist releases proteins in their wild-type folded states or whether it induces their denaturation, partial unfolding, or precipitation. We illustrate the method by studying lead compounds that have recently been reported to block the MDM2-p53 interaction. Activation of p53 in tumor cells by inhibiting its interaction with MDM2 offers new strategy for cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16173750     DOI: 10.1021/ja052143x

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  22 in total

1.  Advances in Nuclear Magnetic Resonance for Drug Discovery.

Authors:  Robert Powers
Journal:  Expert Opin Drug Discov       Date:  2009-10-01       Impact factor: 6.098

2.  Transient protein states in designing inhibitors of the MDM2-p53 interaction.

Authors:  Michal Bista; Siglinde Wolf; Kareem Khoury; Kaja Kowalska; Yijun Huang; Ewa Wrona; Marcelino Arciniega; Grzegorz M Popowicz; Tad A Holak; Alexander Dömling
Journal:  Structure       Date:  2013-10-24       Impact factor: 5.006

3.  Fluorescence and solution NMR study of the active site of a 160-kDa group II intron ribozyme.

Authors:  Orlando H Gumbs; Richard A Padgett; Kwaku T Dayie
Journal:  RNA       Date:  2006-08-07       Impact factor: 4.942

Review 4.  Studies of metabolite-protein interactions: a review.

Authors:  Ryan Matsuda; Cong Bi; Jeanethe Anguizola; Matthew Sobansky; Elliott Rodriguez; John Vargas Badilla; Xiwei Zheng; Benjamin Hage; David S Hage
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2013-11-25       Impact factor: 3.205

5.  Human melanoma inhibitory protein binds to the FN12-14 Hep II domain of fibronectin.

Authors:  King Tuo Yip; Xueyin Zhong; Nadia Seibel; Oliver Arnolds; Miriam Schöpel; Raphael Stoll
Journal:  Biointerphases       Date:  2017-05-31       Impact factor: 2.456

Review 6.  Molecular targeted approaches to cancer therapy and prevention using chalcones.

Authors:  Danielle D Jandial; Christopher A Blair; Saiyang Zhang; Lauren S Krill; Yan-Bing Zhang; Xiaolin Zi
Journal:  Curr Cancer Drug Targets       Date:  2014       Impact factor: 3.428

7.  Trapping moving targets with small molecules.

Authors:  Gregory M Lee; Charles S Craik
Journal:  Science       Date:  2009-04-10       Impact factor: 47.728

8.  Therapeutic considerations for Mdm2: not just a one trick pony.

Authors:  Jason A Lehman; Jacob A Eitel; Christopher N Batuello; Lindsey D Mayo
Journal:  Expert Opin Drug Discov       Date:  2008-11       Impact factor: 6.098

9.  Detecting protein-protein interactions by Xe-129 NMR.

Authors:  Zhuangyu Zhao; Benjamin W Roose; Serge D Zemerov; Madison A Stringer; Ivan J Dmochowski
Journal:  Chem Commun (Camb)       Date:  2020-09-22       Impact factor: 6.222

10.  The Sam domain of the lipid phosphatase Ship2 adopts a common model to interact with Arap3-Sam and EphA2-Sam.

Authors:  Marilisa Leone; Jason Cellitti; Maurizio Pellecchia
Journal:  BMC Struct Biol       Date:  2009-09-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.